Progen to license cancer R&D
Wednesday, 18 September, 2002
Drug developer Progen Industries is licensing development rights to a new patented cancer therapy from the University of New South Wales.
The agreement with the university's commercialisation arm, UniQuest, gives Progen exclusive world rights to technology covering a novel drug formulation and delivery mechanism with the potential to treat multiple cancers.
Progen is already in trials with its flagship anti-cancer drug, PI-88. It sees the newly-licensed therapy, labelled PI-166, as a complementary stablemate to PI-88 which will help fill Progen's drug pipeline.
PI-166 is currently in late-stage pre-clinical development and Progen will fund further R&D, including human trials, to provide further validation of the therapy.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
